×
Nutriband Receivables 2016-2024 | NTRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Nutriband receivables from 2016 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Nutriband Receivables 2016-2024 | NTRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Nutriband receivables from 2016 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.7B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$19.3B
Merck (MKKGY)
$18.8B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.4B
Summit Therapeutics (SMMT)
$13.6B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$11.8B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7.2B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.3B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2.4B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Centessa Pharmaceuticals (CNTA)
$2.1B
Evotec AG (EVO)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.7B
Recursion Pharmaceuticals (RXRX)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B